These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11906289)

  • 1. Toward an optimal joint recognition of the S1' subsites of endothelin converting enzyme-1 (ECE-1), angiotensin converting enzyme (ACE), and neutral endopeptidase (NEP).
    Inguimbert N; Coric P; Poras H; Meudal H; Teffot F; Fournié-Zaluski MC; Roques BP
    J Med Chem; 2002 Mar; 45(7):1477-86. PubMed ID: 11906289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
    Coric P; Turcaud S; Meudal H; Roques BP; Fournie-Zaluski MC
    J Med Chem; 1996 Mar; 39(6):1210-9. PubMed ID: 8632427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.
    Tikkanen I; Tikkanen T; Cao Z; Allen TJ; Davis BJ; Lassila M; Casley D; Johnston CI; Burrell LM; Cooper ME
    J Hypertens; 2002 Apr; 20(4):707-14. PubMed ID: 11910307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A three-dimensional model of endothelin-converting enzyme (ECE) based on the X-ray structure of neutral endopeptidase 24.11 (NEP).
    Bur D; Dale GE; Oefner C
    Protein Eng; 2001 May; 14(5):337-41. PubMed ID: 11438756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study of substrate specificity of a new peptide substrate of endothelin converting enzyme].
    Gureeva TA; Kugaevskaia EV; Pozdnev VF; Prozorovskiĭ VN; Eliseeva IuE; Solov'eva NI
    Biomed Khim; 2007; 53(2):172-80. PubMed ID: 17639718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutagenesis of Glu403 to Cys in rabbit neutral endopeptidase-24.11 (neprilysin) creates a disulphide-linked homodimer: analogy with endothelin-converting enzyme.
    Hoang MV; Sansom CE; Turner AJ
    Biochem J; 1997 Nov; 327 ( Pt 3)(Pt 3):925-9. PubMed ID: 9581575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors.
    Jullien N; Makritis A; Georgiadis D; Beau F; Yiotakis A; Dive V
    J Med Chem; 2010 Jan; 53(1):208-20. PubMed ID: 19899765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme.
    Kukkola PJ; Savage P; Sakane Y; Berry JC; Bilci NA; Ghai RD; Jeng AY
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S65-8. PubMed ID: 8587470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme.
    Battistini B; Daull P; Jeng AY
    Cardiovasc Drug Rev; 2005; 23(4):317-30. PubMed ID: 16614731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple ACE-ECE-NEP inhibition in heart failure: a comparison with ACE and dual ECE-NEP inhibition.
    Mellin V; Jeng AY; Monteil C; Renet S; Henry JP; Thuillez C; Mulder P
    J Cardiovasc Pharmacol; 2005 Sep; 46(3):390-7. PubMed ID: 16116347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
    Ksander GM; Savage P; Trapani AJ; Balwierczak JL; Jeng AY
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S71-3. PubMed ID: 9595404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.
    Fournié-Zaluski MC; Coric P; Turcaud S; Rousselet N; Gonzalez W; Barbe B; Pham I; Jullian N; Michel JB; Roques BP
    J Med Chem; 1994 Apr; 37(8):1070-83. PubMed ID: 8164250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-[2-(Indan-1-yl)-3-mercapto-propionyl] amino acids as highly potent inhibitors of the three vasopeptidases (NEP, ACE, ECE): In vitro and In vivo activities.
    Inguimbert N; Poras H; Teffo F; Beslot F; Selkti M; Tomas A; Scalbert E; Bennejean C; Renard P; Fournié-Zaluski MC; Roques BP
    Bioorg Med Chem Lett; 2002 Aug; 12(15):2001-5. PubMed ID: 12113828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.
    Fournie-Zaluski MC; Coric P; Thery V; Gonzalez W; Meudal H; Turcaud S; Michel JB; Roques BP
    J Med Chem; 1996 Jun; 39(13):2594-608. PubMed ID: 8691458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell surface metallopeptidases involved in blood pressure regulation: structure, inhibition and clinical perspectives.
    Roques BP
    Pathol Biol (Paris); 1998 Mar; 46(3):191-200. PubMed ID: 9769915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging concepts of neurohumoral modulation in the treatment of congestive heart failure.
    Mulder P; Thuillez Ch
    Arch Mal Coeur Vaiss; 2002 Sep; 95(9):821-6. PubMed ID: 12407798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of human endothelin-converting enzyme I complexed with phosphoramidon.
    Schulz H; Dale GE; Karimi-Nejad Y; Oefner C
    J Mol Biol; 2009 Jan; 385(1):178-87. PubMed ID: 18992253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines.
    Usmani BA; Harden B; Maitland NJ; Turner AJ
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():314S-317S. PubMed ID: 12193112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of functionally active endothelin-converting enzyme by chronic neutral endopeptidase inhibition in experimental atherosclerosis.
    Grantham JA; Schirger JA; Wennberg PW; Sandberg S; Heublein DM; Subkowski T; Burnett JC
    Circulation; 2000 Apr; 101(16):1976-81. PubMed ID: 10779465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel mechanism of inhibition of human angiotensin-I-converting enzyme (ACE) by a highly specific phosphinic tripeptide.
    Akif M; Schwager SL; Anthony CS; Czarny B; Beau F; Dive V; Sturrock ED; Acharya KR
    Biochem J; 2011 May; 436(1):53-9. PubMed ID: 21352096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.